Scancell Share Discussion Threads

[marcusl2] 12/2/2024 13:27

(the indication Genmab did not get)


CONCLUSIONS
 Sialyl-di-lewisa is expressed on the surface of many cancer cell types

 CAR T cells can be engineered to recognised sialyl-di-lewisausing the 129 antibody previously characterised; 129 CAR T cells are activated by sialyl-di-lewisa expressing cancer cell lines

 129 CAR T cells are associated with a strong anti-tumour effect in vivo in NSG mice
Ccanti-sialyl-di-lewisa CAR T cells to target tumour cells.
HER2 CAR T Tumour only

129 CAR T NT-T cells C Anti-sialyl-di-lewisa CAR T cells can induce a strong anti-tumour response

[jimmythegong] 09/2/2024 12:20

From your mouth to God's and Lindy's ears....

[marcusl2] 09/2/2024 09:32

renal cell carcinoma

[marcusl2] 09/2/2024 09:30

Anticipated news;

Possibly first patient dosed with iScib+ RNS ?

Modi-1 in renal cell carcinoma in combination with double CPI therapy pending protocol amendment by the MHRA.

Two deals this year for GlyMab® and AvidiMab® platforms. Active discussions ongoing with pharmaceutical and biotech companies.

Genmab starting Phase I with SC129, milestone payment.

Data from both the SCOPE and ModiFY trials

Plus maybe something out of left field.

[marcusl2] 08/2/2024 15:42

CW


THE GREAT NATIONAL CANCER VACCINE SUMMIT
01 May, 2024

[sci102] 08/2/2024 13:36

I do have to admit though that it was smart to target second line mesothelioma, they may get away with being roughly equal, but UV proving very safe to not give it a chance.

[markingtime] 08/2/2024 13:32

Fast tracking is a potential wild card in the cancer vaccine space. Could lead to equally fast movements in share prices if cancer vaccines start to get traction with regulators.Remember this area was particularly highlighted by Hunt when he announced the fast-tracking plan.

[sci102] 08/2/2024 13:16

Also keep in mind that fast track is a lot about the condition itself (unmed need), that doesn't mean obviously that everyone that targets the same condition [gets fast track]. But also, many criteria are about low toxicity, which cancer vaccines like this generally are. It's an "OK, lets see what happens in a larger population" for sure, but ir's not the slam dunk you may believe. For example, within the context of fast track there is also Accelerated Approval and Priority Review, which they did not get, at least not yet.

[marcusl2] 08/2/2024 10:54

Just a comparison of what we have atm Sci.

[sci102] 08/2/2024 10:30

Msrcus

Since the PFS/OS data is terrible, the ORR doesn't even matter anymore. It just doesn't work well enough.

[sci102] 08/2/2024 10:24

3n. Looked at the latest co presentation. As suspected, that 27% risk reduction is complete nonsense, sorry. Look at the OS kaplan graph there is basically no difference and it is not statistically significant. Far from actually. I hope that is not the data you were counting on. Also there is no difference in PFS by Blinded Independent Central Review while there is some difference when assesed by the investigator. This is exactly the kind of company I would never ever touch.
.

[marcusl2] 08/2/2024 09:07

You didn`t explain that in your 179 post. Good to see.

Median OS 15.4 months with UV1 plus IPI-NIVO versus 11.1 months with IPI-NIVO

Objective response rate (ORR)
• UV1 plus IPI-NIVO: 31%
• IPI-NIVO: 16%

Early data on Scancell`s Modi-1 vaccine

44% disease control rate (DCR) in ovarian cancer patients in ModiFY monotherapy trial

Dr David Pinato, Principal Investigator at Imperial College, commented: “Advanced ovarian cancer is an aggressive cancer which is hard to treat. The early efficacy data showing that the Modi-1 vaccine is stabilising this advanced disease is very encouraging”.

We are hoping to get permission to combine with CPIs.

Both cancers are immune deserts and extremely hard to treat.

The immune desert is exactly how it sounds. There is a tumour, but no T Cell army is present to mount an attack. There is a total lack of an immune response present in the tumour.

“Immune-desert” tumours lack CD8+ T cells in both the tumour bed and the tumour edges.

PD-1, CTLA-4 check points and cancer vaccines will hopefully improve treatment.

[3nobody] 08/2/2024 08:28

Sci102,

NIPU was the trial for Meso.
You can look here for both video and pdf presentations.

hxxps://ultimovacs.com/investors/presentations-and-publications

[3nobody] 08/2/2024 08:22

marcus,

Ultimovacs trial in Meso is based on CM-743 as a reference! I am very familiar with CM743.

You do realize Ultimovacs 27% improvement is with Ipi+Nivo in control arm?
CM743 was in first line. Ultimovacs in second line showing 27% improvement ON TOP of Ipi+Nivo.

[sci102] 08/2/2024 07:24

27% risk reduction is not a lot. What is the p value/CI? Do you have a link to the presentation?

[3nobody] 08/2/2024 07:18

marcus,

Just a quick follow up on earlier discussions.

I have listened through AGM from nov-23 where Lindy thinks Ultimovacs approach is wrong because UV1 is a single antigen and therefore could have a problem with antigen escape (loss).

6 weeks prior AGM Ultimovacs showed significant and clinically improvement in overall survival in second line malignant mesothelioma, reducing risk of death by 27%.

This is randomized trial, OS - the "gold standard". Very difficult cancer to treat and the excact same vaccine as used in Melanoma.

I therefore think Lindy's statement about Ultimovacs using wrong approuch is completely meaningless.

[markingtime] 07/2/2024 15:50

Quite right, Bermudashorts!

[sci102] 07/2/2024 15:42

You are probably right. But there is always the chance there is another presentation before that.

[bermudashorts] 07/2/2024 15:32

Sorry, I know this won't be popular but I disagree. Sarah Danson is currently involved as investigator in at least 5 other active melanoma trials in addition to SCOPE and I'm sure she'll give an overview of those as well as other promising studies. However, any new SCIB1 results would be presented either by Lindy Durrant or Poulam Patel as PI at a more high profile scientific conference rather than a study investigator at a charity patient conference.

[chilltime] 07/2/2024 14:57

Sci

I agree, surely an update via news before that presentation.

News to date includes 11 patients with various scans and 2 with a first scan and no confirmation scan.

Currently all 16 patients are past their first and second confirmation scan (19 weeks)

So in number terms they have 2 confirmation scans for patient 12 and 13 and first and confirmation scans for patients 14-16.

Plus some 25 week scans and so on.

That’s the first cohort done with data on all now available.

It would be odd to present without giving the data of all 16, but then to do that they need to inform the market first.

Surely as time passes some further patients will experience complete responses, judging by reports so far.

If a patient had a 20mm tumour and reduced 94% it’s just 1.2mm now which is tiny.

[marcusl2] 07/2/2024 14:10

Yes whoever licenses iScib+ (if successful) will likely expand into resected, stage 2 Melanoma etc.



I still think someone may take the whole Immunobody platform. That could be a very nice deal.

If 2020 rates continue, the burden from melanoma is estimated to increase to 510 000 new cases (a roughly 50% increase) and to 96 000 deaths (a 68% increase) by 2040.